75N91019F00138↗

Name: 75N91019F00138: CMC Support for Ncats Rare Disease Platform Gene Therapy Trial Projects
Creator: SpendQuery
License: https://www.usa.gov/government-works

Leidos Biomedical Research Inc received this contract from Nih Nci, National Institutes of Health: $17.32M obligated so far for health r&d services; health care services; applied research. It runs to 2031-03-31.

Key facts · data as of Oct 23, 2026

Recipient: Leidos Biomedical Research Inc
Awarding agency: National Institutes of Health (Department of Health and Human Services)
Contracting office: Nih Nci (75N910)
Obligated to date: $17.32M
Potential value: $30.07M
Ends: 2031-03-31

Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.

Cite this page: SpendQuery, Award 75N91019F00138, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75N91019F00138_7529_75N91019D00024_7529

Leidos Biomedical Research Inc: all federal awards · Department of Health and Human Services: spending · Nih Nci: what it buys

CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS

Delivery Order · National Institutes of Health · to Leidos Biomedical Research Inc (UEI HV8BH9BPG8Y9) · data as of 2026-10-23

Obligated to date$17.32M10 actions

Current value$30.07Mwith options exercised

Period2019-09-23 → 2031-03-31current end date

What it is

Product or service: Health R&D Services; Health Care Services; Applied Research (PSC AN12)
Industry: Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
Contracting office: Nih Nci (75N910)
Competition: Full and open competition
Pricing: Cost plus fixed fee
How it was bought: Single-award IDIQ · under 75N91019D00024
Solicitation: N02CO7240681
Where the work is: Frederick, MD · district MD-06

Obligations by fiscal year

FY2023$1.78M

FY2024$5.08M

FY2025$4.49M

FY2026$5.98M

SpendQuery holds FY2023 on; earlier years are on USAspending.gov.

Subcontractors: where the money went next

No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.

Every action

10 actions since 2023-09-11. Each is a modification or amendment with the money it added or took back.

Date	Modification	Kind	Amount	What the agency wrote
2026-09-23	P00014	Administrative change	$1.81M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2026-09-17	P00013	Administrative change	$4.17M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2026-05-19	P00012	Administrative change	$0	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2025-09-17	P00011	Administrative change	$2.48M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2025-08-26	P00010	Administrative change	$2.01M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2025-05-02	P00009	Administrative change	$0	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2024-09-19	P00008	Option exercised	$5.08M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2024-07-18	P00007	Administrative change	$0	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2024-06-07	P00006	Administrative change	$0	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS
2023-09-11	P00005	Supplemental agreement (work within scope)	$1.78M	CMC SUPPORT FOR NCATS RARE DISEASE PLATFORM GENE THERAPY TRIAL PROJECTS

Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗

Putting the award page together from the records…